NMDA-glycine antagonists

Christensen, D., IdSnpSan-Heikkila, J. J., Guilbaud, G., Kayser V. The antinociceptive effect of combined systemic administration of morphine and the glycine/NMDA antagonist, (+)-HA-966 in a rat model of peripheral neuropathy, Br. J. Pharmacol. 1998, 125, 1641-1650. 

Carboxy-indolines and indoles as potential glycine/NMDA antagonists effect of five-membered ring conformation of affinity. Bioorg. Med. Chem. Lett. 2, 1627-1630. 

The synthesis of Merck s glycine NMDA receptor or antagonist L-701,324 is illustrative, it can be prepared in one step by use of this procedure the reported synthetic procedure comprises several reaction steps. 

Nyce, P., Salituro, F. G. Pharmacological characterization ofMDL 105,519, an NMDA receptor glycine site antagonist, Eur. J. Pharmacol. 1997, 323, 181-192. 

Lutfy, K. and Weber, E. Attenuation of nociceptive responses by ACEA-1021, a competitive NMDA receptor/glycine site antagonist, in the mice, Brain Res. 1996, 743, 17-23. 

Priestley, T., Laughton, P., Macaulay, A. J., Hill, R. G., Kemp, J. A. Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324, Neuropharmacology 1996, 35, 1573-1581. 

NMDA glycine-site antagonists <03BMCL3553>, 5-aryl-pyrazolo[3,4-6]pyridazines as inhibitors of glycogen synthase kinase-3 <03BMCL1581>, and 3-arylamino- and 3-cycloalkylamino-5,6-diphenylpyridazines as ACAT inhibitors <03AP563>. 

---